Badanie STOP‑ASPIRIN: odstawienie kwasu acetylosalicylowego u pacjentów >65 lat ze stabilnym zespołem wieńcowym jest bezpieczne

Enrollment

After signing the consent form, you become a participant in the trial.

Your basic personal data and medical history are recorded.

Baseline Assessment

A detailed evaluation of your heart condition and current medications is performed.

Laboratory tests and a physical Examination are done to establish a starting point for the study.

Randomization

The study team assigns you, by chance, to one of two groups.

One Group continues to receive aspirin, the other Group stops taking aspirin.

Medication phase

If you are assigned to the continuation Group, you take one tablet of aspirin (150 mg) by mouth each day.

The tablet is either a gastro‑resistant tablet (magnyl dak) or a film‑coated tablet (hjertemagnyl), both containing the same amount of active substance.

If you are assigned to the discontinuation Group, you do not take any aspirin tablets for the duration of the study.

Regular follow‑up visits

You attend scheduled visits at intervals defined by the protocol (for example, after one month, three months, and then every six months).

During each visit, your health status is checked, and any cardiovascular events, bleeding, or other symptoms are recorded.

Monitoring of outcomes

The study records important events such as cardiovascular death, fatal bleeding, intracranial bleeding, ischemic stroke, heart attack, and other major bleeding.

Additional information about quality of life, minor bleeding, abdominal discomfort, and angina symptoms is also collected.

Final visit and study closure

At the end of the trial period (up to three years from the first enrollment), you attend a final Assessment.

All collected data are reviewed, and the study is concluded for your participation.